c19early.org COVID-19 treatment researchAzithromycinAzithromycin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
 
More

Supplementary Data — Azithromycin for COVID-19: real-time meta analysis of 20 studies

@CovidAnalysis, December 2024, Version 9V9
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Q-PROTECT Omrani (DB RCT) -33% 1.33 [0.30-5.86] hosp. 4/152 3/152 Improvement, RR [CI] Treatment Control Q-PROTECT Omrani (DB RCT) 67% 0.33 [0.04-3.17] progression 1/152 3/152 Q-PROTECT Omrani (DB RCT) -100% 2.00 [0.51-7.85] no recov. 6/152 3/152 Q-PROTECT Omrani (DB RCT) -4% 1.04 [0.89-1.22] viral load 152 (n) 152 (n) Madamombe 40% 0.60 [0.40-0.98] death 672 (all patients) Lounnas (PSM) 27% 0.73 [0.61-0.87] death/ICU n/a n/a Kuderer -27% 1.27 [0.67-2.32] death 12/93 41/486 Kuderer -152% 2.52 [1.68-3.63] death 45/181 41/486 COALITION I Cavalcanti (RCT) 57% 0.43 [0.13-1.45] death 5/172 7/159 COALITION I Cavalcanti (RCT) 45% 0.55 [0.13-2.28] death 3/172 5/159 COALITION I Cavalcanti (RCT) -54% 1.54 [0.71-3.35] ventilation 19/172 12/159 COALITION I Cavalcanti (RCT) 18% 0.82 [0.47-1.43] 7-point status 172 (n) 159 (n) COALITION II Furtado (RCT) -8% 1.08 [0.79-1.47] death 90/214 73/183 COALITION II Furtado (RCT) -3% 1.03 [0.76-1.38] death 66/214 55/183 COALITION II Furtado (RCT) 30% 0.70 [0.47-1.04] misc. 214 (n) 183 (n) COALITION II Furtado (RCT) 26% 0.74 [0.51-1.06] misc. 214 (n) 183 (n) Sekhavati (RCT) 67% 0.33 [0.01-7.96] death 0/56 1/55 Sekhavati (RCT) 86% 0.14 [0.01-2.68] ventilation 0/56 3/55 Sekhavati (RCT) 72% 0.28 [0.06-1.29] ICU 2/56 7/55 Sekhavati (RCT) 23% 0.77 [0.62-0.96] hosp. time 56 (n) 55 (n) Yeramaneni 7% 0.93 [0.49-1.78] death 4,003 (n) 3,155 (n) RECOVERY Abaleke (RCT) 3% 0.97 [0.87-1.07] death 561/2,430 1,162/4,881 RECOVERY Abaleke (RCT) 3% 0.97 [0.88-1.07] death 496/2,430 1,028/4,881 RECOVERY Abaleke (RCT) 8% 0.92 [0.79-1.07] ventilation 211/2,430 461/4,881 PRINCIPLE Butler (RCT) 50% 0.50 [0.10-2.59] ventilation 2/496 5/625 PRINCIPLE Butler (RCT) 24% 0.76 [0.18-3.15] ICU 3/495 5/625 PRINCIPLE Butler (RCT) 16% 0.84 [0.38-1.85] oxygen 10/497 15/625 PRINCIPLE Butler (RCT) 9% 0.91 [0.49-1.72] hosp. 16/500 22/629 PRINCIPLE Butler (RCT) 7% 0.93 [0.81-1.05] no recov. 500 (n) 823 (n) ATOMIC2 Hinks (RCT) -1% 1.01 [0.06-16.1] death 1/145 1/147 ATOMIC2 Hinks (RCT) 1% 0.99 [0.49-2.00] death/hosp. 15/145 17/147 ATOMIC2 Hinks (RCT) 8% 0.92 [0.45-1.77] death/hosp. 15/145 17/147 ATOMIC2 Hinks (RCT) 80% 0.20 [0.01-4.05] progression 0/119 2/114 AlQadheeb (ICU) -22% 1.22 [0.96-1.55] death 467/775 36/73 ICU patients Yilgwan 67% 0.33 [0.19-0.58] death 1,619 (n) 1,843 (n) Atefi 85% 0.15 [0.01-2.63] death 0/18 4/42 Mehrizi 32% 0.68 [0.66-0.70] death population-based cohort Donida 7% 0.93 [0.56-1.57] death 180/548 101/175 PiƱana 58% 0.42 [0.20-0.89] death n/a n/a Huh -54% 1.54 [0.48-2.65] progression 3/6 875/2,799 Huh 42% 0.58 [0.30-1.12] cases case control Loucera 15% 0.85 [0.76-0.95] death 2,465 (n) 13,503 (n) Dugot 12% 0.88 [0.83-0.94] cases case control Azithromycin COVID-19 outcomes c19early.org December 2024 Favors azithromycin Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit